Drug Database
PI

piperacillin (piperacillin, KRKA / Isipen)

✓ Approved

Krka · Small Molecule · Small Molecule

What is piperacillin?

piperacillin is a small molecule developed by Krka. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namespiperacillin, KRKA, Isipen
CompanyKrka
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Krka

Therapeutic Indications

piperacillin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedBMC microbiology2026-07-17

Genomic analysis reveals multi-lineage carbapenem-resistant Pseudomonas aeruginosa mimicking a hospital outbreak.

Yalçın Süleyman S, Ünlü Çelebi Sezin S, Yıldız Salih Rıza Ozan SRO, Kurt Azap Özlem Ö et al.

Pseudomonas aeruginosa is a major cause of nosocomial infections, often exhibiting multidrug resistance (MDR) and high genetic adaptability. This study investigated temporal cluster of MDR P. aeruginosa isolates obtained from five different hospitalized patients within a single healthcare facility. The isolates shared similar antimicrobial resistance patterns, suggesting a common source or transmission event. However, pulsed-field gel electrophoresis (PFGE) genotyping identified four distinct clones, indicating clonal heterogeneity rather than a single-strain outbreak. To further elucidate the genetic basis of resistance, virulence, and genomic diversity, whole-genome sequencing (WGS) was performed. All the isolates were resistant to cefepime, ceftazidime, meropenem, ciprofloxaxin, levofloxaxin, piperacillin-tazobactam; three of them were susceptible to amikacin, and all were susceptible to colistin. Resistome analysis revealed a diverse array of antimicrobial resistance genes, including chromosomal class C (blaPDC-16/37/374) and D (blaOXA-50 family:395/847/848/906) and blaVIM-2 type β-lactamases, and a wide variety of efflux pumps (such as MexAB-OprM, MexCD-OprJ MexGHI-OpmD, MexJK-OprM, MexMN-OprM, MexPQ-OpmE, MuxABC-OpmB). Virulome analysis identified key pathogenicity determinants related to biofilm formation, adherence, motility, immune evasion, toxin and other virulence traits. Multiple mobile genetic elements were determined, suggesting horizontal gene transfer (HGT) as a significant factor in the dissemination of resistance traits. These findings demonstrate that nosocomial outbreak-like event of MDR P. aeruginosa can involve multiple unrelated clones co-circulating within the same hospital environment, challenging traditional epidemiological assumptions. Despite a high degree of core genome synteny and similar resistance profiles, the identification of four distinct clones among simultaneous patient cases indicates that the outbreak was not caused by a single strain. These results further emphasize the potential for multiple co-circulating clones in MDR P. aeruginosa outbreaks and challenge assumptions of single-source transmission. Whole-genome sequencing plays a critical role in understanding transmission dynamics and guiding infection control strategies.

PMID 42464129
Read full article →
PubMedJournal of infection and public health2026-07-17

Transforming an antimicrobial stewardship program at a tertiary military medical center in Saudi Arabia: An institutional quality improvement report.

Almaghrabi Rana R, Alhusain Fahad F, Alfahad Wafa W, Alabdulsalam Asma A et al.

Antimicrobial resistance remains a major public health challenge, the World Health Organization has reaffirmed the priority of resistant Gram-negative pathogens in its 2024 Bacterial Priority Pathogens List and 2025 GLASS surveillance report. In Saudi Arabia, recent surveillance and review data continue to show substantial use of Watch-category antimicrobials and ongoing concern regarding extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales, underscoring the need for mature institutional antimicrobial stewardship programs (ASPs). To describe the implementation of a restructured antimicrobial stewardship program (ASP) at a tertiary military medical center in Saudi Arabia and to report early descriptive changes in prespecified stewardship and quality indicators, including antimicrobial consumption, prescribing appropriateness, patient-level stewardship intervention patterns, emergency department blood-culture quality, and surgical antibiotic prophylaxis adherence. This single-center institutional quality improvement report was conducted at a 1,200-bed tertiary military medical center in Riyadh, Saudi Arabia. The overall implementation period extended from January 2024 through September 2025. Foundational ASP activities had existed since 2012 for adult services and were expanded to pediatric services in 2017; a comprehensive restructuring toward a Center of Excellence model began in 2024. A multidisciplinary stewardship team implemented a restructured program incorporating prospective audit and feedback in high-risk inpatient units, tiered antimicrobial restrictions, electronic clinical decision support, diagnostic stewardship in the emergency department, and procedure-specific prophylaxis monitoring. Hospital-wide antimicrobial consumption is reported using a 2024 reference period during early restructuring, whereas systematic clinical indicator monitoring for other domains began in early 2025 with domain-specific observation windows. Analyses were descriptive; no inferential statistical testing was performed. The report follows the SQUIRE 2.0 reporting framework. Hospital-wide antimicrobial consumption showed reductions in days of therapy (DOT) per 1000 patient-days for meropenem (28.5%), piperacillin-tazobactam (20.3%), vancomycin (22.3%), and tigecycline (34.4%), with a concurrent 20.8% increase in ceftriaxone. In audited high-risk inpatient units (intensive care, oncology, and transplant), overall prescribing appropriateness increased from 54% to 89%. Between January and September 2025, 666 patient-level stewardship recommendations were documented: stop therapy (324), recommend infectious diseases consultation (241), dose adjustment (66), de-escalation (29), and other recommendations (6). In the emergency department, blood-culture ordering appropriateness improved from 70% to 97%, and the contamination rate declined from 3.5% to 0.4% between January and June 2025. Cesarean-section surgical prophylaxis adherence reached 100% for antibiotic choice, timing, and dose, while duration adherence improved from 27% to 46%. Restructuring of an existing antimicrobial stewardship program at a tertiary military medical center was accompanied by favorable descriptive changes across several prespecified stewardship and quality indicators during the reporting period. The transition from a predominantly restrictive model toward facilitative, consultation-based stewardship may offer practical implementation lessons for similarly resourced tertiary-care settings. Because this is a single-center descriptive quality-improvement report without inferential analysis or a formal control period, these observations should not be interpreted as causal; longer follow-up and more rigorous evaluation designs are needed to assess sustainability.

PMID 42462644
Read full article →
PubMedInternational medical case reports journal2026-07-16

Purple Urine Bag Syndrome in a 26-Year-Old Woman Living with HIV and Metastatic Spinal Cord Compression: A Case Report.

Wasswa Vincent V, Okema James Nelson JN, Otto Kim Andrew KA, Lwembawo Kiragga Denis KD et al.

Purple urine bag syndrome (PUBS) is a rare complication of urinary catheterization in which urine, catheter and collection bag develop a characteristic purple discoloration from bacterial metabolism of dietary tryptophan to indigo and indirubin. It is reported almost exclusively in elderly, chronically catheterized women, with very few reports from sub-Saharan Africa. A 26-year-old para 2+0 woman, six months postpartum and living with HIV (CD4 = 194 cells/µL), presented with a two-month history of progressive lower-limb weakness, urinary and fecal incontinence and chronic constipation, with three days of fever and loin pain, having been catheterized three times in the preceding four weeks. She was febrile and paraplegic with a T12 sensory level. Empirical ceftriaxone was started for presumed urosepsis; two days later the urine and bag turned purple. Urine culture grew Escherichia coli at >105 CFU/mL, multidrug-resistant but sensitive to piperacillin/tazobactam. Therapy was escalated and the catheter exchanged; the urine cleared within 24 hours with symptomatic improvement. MRI showed a lytic T10/T11 lesion with cord compression and hepatic and pulmonary nodules consistent with metastatic disease; tumor markers were within normal limits, narrowing but not excluding the primary. Recognized PUBS risk factors include prolonged catheterization, female sex, neurogenic bladder, immobility, chronic constipation and renal disease, occurring mostly in elderly women. Our patient was young but had several of these factors, plus multidrug-resistant bacteriuria and HIV-related immunosuppression that may have increased her susceptibility to infection. Cumulative risk-factor burden, rather than age alone, appears to drive the syndrome; empirical ceftriaxone failed, reflecting rising regional cephalosporin resistance. PUBS is a visible indicator of catheter-associated urinary tract infection that can occur outside the typical elderly demographic when risk factors converge and should prompt urgent culture, catheter exchange and culture-directed antibiotics to prevent progression to urosepsis: to our knowledge, the first reported case from Uganda.

PMID 42459895
Read full article →
PubMedJournal of clinical medicine2026-07-15

Factors Affecting Vancomycin and Piperacillin-Tazobactam-Induced Nephrotoxicity.

Day Mollie VanNatta MV, Munshi Ruhul R, Picard Kalyn K, Malek Alexandre E AE

Background/Objectives: Nephrotoxicity caused by use of vancomycin and piperacillin-tazobactam has been heavily debated, and specific impact of this combination on development of acute kidney injury (AKI) has remained uncertain. We sought to further elucidate the risk factors contributing to nephrotoxicity. Methods: We conducted a retrospective cohort study at our academic medical center from May 2019 to March 2023. We included adult patients who received at least 48 h of dual vancomycin and piperacillin-tazobactam therapy. The primary outcome is incidence of kidney injury along with determinants of AKI. Patients were stratified into two groups according to occurrence of AKI or its absence. Demographic features, concomitant use of nephrotoxic agents, site of infection, use of vasopressors, duration of therapy, and vancomycin-level parameters were compared. Results: Of 350 patients, AKI occurred in 89 patients (25.4%). The 30-day mortality was comparable between the two groups. No significant differences were observed in age, gender, race, or comorbidities, although more AKI cases occurred in African American patients (51.7%). Elevated initial vancomycin trough and estimated area under the curve/minimum inhibitory concentration levels, higher mean body mass index (BMI), and use of intravenous (IV) contrast were more frequently observed in the AKI group. Conclusions: We demonstrated that 25.4% of patients receiving vancomycin and piperacillin-tazobactam combination experienced AKI, while higher BMI and use of concomitant IV contrast were significantly associated with increased nephrotoxicity. Therefore, we suggest proceeding with caution regarding use of vancomycin and piperacillin-tazobactam in patients with elevated BMI and those who have received IV contrast.

PMID 42452481
Read full article →
PubMedAntimicrobial agents and chemotherapy2026-07-15

Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".

Laporte-Amargos Julia J, Ulldemolins Marta M, Hernández-Mitre María Patricia MP, Roberts Jason A JA et al.

PMID 42455077
Read full article →
PubMedJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2026-07-15

Blood culture collection practice prior to empiric piperacillin/tazobactam in patients requiring hospitalization: a potential target for antimicrobial stewardship from a single-center retrospective observational study.

Kitaura Satoshi S, Okamoto Koh K, Yamaguchi Ryo R, Yamamoto Takehito T et al.

The current clinical paradigm recommends appropriate blood culture collection based on the patient's severity and suspected diagnosis. Beyond providing microbiological diagnosis, blood cultures can facilitate the de-escalation of broad-spectrum antibiotics. Nonetheless, blood culture collection practices upon prescription of broad-spectrum antibiotics remain largely unexplored. A retrospective observational study was conducted at a tertiary care academic hospital in Tokyo, Japan. Patients who required hospitalization and underwent empiric piperacillin/tazobactam prescription on day of admission from 2016/4/1 to 2017/12/31 were included. Patients ≤18 years old, who finished piperacillin/tazobactam on or before day 1, and duplicates were excluded. A total of 250 patients were randomly selected to assess the frequency and factors associated with blood culture collection. Blood culture collection was fulfilled in 163 patients (65.2%). The use of immunosuppressive agents (odds ratio [OR], 3.47; confidence interval [CI], 1.43-9.43), systemic inflammatory response syndrome criteria ≥2 (OR, 4.42; CI, 2.22-9.23) were associated with blood culture collection. On the contrary, intraabdominal infection (OR, 0.28; CI 0.11-0.65), and surgical specialty (OR, 0.33; CI, 0.18-0.61) were associated with withholding of blood culture collection. Withholding of blood culture collection was observed prior to empiric piperacillin/tazobactam prescription in one-third of patients warranting hospitalization. Surgical specialty was associated with potential missed opportunities for blood culture collection. Tailored implementation strategies may optimize blood culture collection practices among different specialties.

PMID 42448102
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about piperacillin